Bristol-Myers Squibb has been granted a patent for a pharmaceutical combination involving a histone deacetylase 6 inhibitor and an epothilone for treating or preventing cancer, particularly ovarian cancer. The method involves administering a therapeutically effective amount of the combination to the subject. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of May 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of ovarian cancer using hdac6 inhibitor and epothilone
A recently granted patent (Publication Number: US11998546B2) discloses a method for treating ovarian cancer by administering a combination of a histone deacetylase 6 (HDAC6) inhibitor and epothilone to a subject in need. The method involves administering a therapeutically effective amount of the HDAC6 inhibitor, with specific mention of epothilone B as the preferred inhibitor. This combination therapy is particularly useful for treating ovarian cancer that is resistant or refractory to paclitaxel, a commonly used chemotherapy drug.
Furthermore, the patent claims specify the administration of the HDAC6 inhibitor and epothilone either simultaneously or at different times. This flexibility in the administration schedule allows for personalized treatment approaches based on the individual needs and responses of the patients. By targeting HDAC6 and utilizing epothilone in combination, the method aims to provide an effective treatment option for ovarian cancer patients, especially those who have not responded well to traditional paclitaxel-based therapies. This innovative approach highlights the potential of combining different classes of drugs to overcome drug resistance and improve treatment outcomes in ovarian cancer.
To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
